mutation density is decreased over active regulatory regions as a whole, relative to their flanking sequences. The authors of that paper proposed that this decrease occurred because active regulatory regions are more accessible than most DNA regions to repair proteins -DNA is typically packaged around proteins called histones, but regulatory regions are unwound for binding by the transcriptioninitiation machinery. This apparent discrepancy with the current studies reflects the fact that, although regulatory regions as a whole are accessible for NER, the repair machinery is unable to access the core sites within those regions at which transcription factors bind ( Fig. 1) .
Certain mutations are considered to be drivers of cancer, because they provide a growth advantage to tumour cells. Such mutations are generally identified by the high frequency at which they occur across patients. However, the current studies highlight that protein binding can also lead to high mutation frequency -and so can other factors, such as late replication of a region during cell division 9 . Understanding how these features co-vary with mutation rate is vital for designing accurate computer algorithms to identify driver mutations 10 . It is notable that the variables affecting mutation rate differ for cancer types and subtypes. For instance, unlike in skin and lung cancer, NER does not have a major role in colon cancer. Accordingly, the current studies found no increase in mutation density at the centres of active promoters in colon-cancer samples.
Errors introduced by DNA replication in colon cells are normally resolved by a process called mismatch repair, which is most effective in genomic regions that replicate early during cell division. Thus, mutation rates in colon-cancer cells are generally lower in earlyreplicating than in late-replicating regions 11 . Mismatch-repair proteins are, however, inactivated in some colon tumours, resulting in the loss of strong correlation between mutation density and replication timing. In fact, the regional 'landscape' of mutation rates can be used to infer the time of mismatch-repair inactivation in the history of a colon tumour.
In the past few years, the complex interplay between DNA-repair mechanisms and genomic properties not originally associated with repair (such as replication timing and DNA accessibility) has become evident, largely thanks to the increasing availability of whole-genome sequences from tumour samples. The need for such sequences from cancer cells has been debated, because they are costly and have limited immediate clinical value 3 .
But the current studies demonstrate the immense potential of whole-genome sequences as a lens through which to examine the cellular processes that shape the cancer genome. Genomic studies such as these lay the groundwork for future diagnostic tools and treatments tailored to individuals.
It remains unclear how many more genomic features that correlate with mutation rate are yet to be found. All mutations are ultimately the result of faulty DNA repair -do we need to know all the details of the many ways in which repair can break down to harness the full power of genomics for cancer care? The increasing number of tumour-genome sequences, coupled with our ever-improving knowledge of the machinery involved in genome function, will hold the answer to this question. ■ 
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t has long been a mystery why neurons in the peripheral nervous system can regenerate long projections called axons following injury, whereas neurons in the central nervous system (CNS) cannot 1 . One difference is that injured CNS axons lose their intrinsic ability to regrow, but studies have also implicated differences in non-neuronal cells called glia 1, 2 , which surround neurons to support them and provide insulation. Damaged glia in the CNS release inhibitors of axon regeneration 1 , and reactive CNS astrocytes -a type of activated glial cell found at the damaged site -also seem to be powerfully inhibitory 3 . Research [1] [2] [3] into spinal-cord injury has centred mostly on the consequences of removing or inhibiting development of the reactive-astrocyte scar. It thus comes as a surprise that Anderson et al. 4 , on page 195 of this issue, find that this scar in fact strongly supports axon regeneration after spinal-cord injury.
Several studies [5] [6] [7] [8] in which reactive astrocytes were ablated following stroke and spinal-cord injury have shown that the glial scar has a beneficial role in reducing inflammation and secondary tissue damage, and in promoting the recovery of neuronal activity. These findings seem at odds with a previous study indicating that reactive astrocytes inhibit axon regeneration 3 (Fig. 1a) . However, this latter study was largely correlational, because it did not directly manipulate reactive astrocytes.
Anderson et al. set out to directly test the role of reactive astrocytes in axon regeneration following experimental spinal-cord injury, in which axons die and retract. In their first set of experiments, the authors prevented the formation of reactive astrocytes using two genetically modified mouse models to ablate or attenuate the glial scar -in the first model, proliferating scar-forming astrocytes were selectively killed 5 , and in the second, the transcription factor STAT3 (which is required for formation of scar-forming reactive astrocytes) was deleted in astrocytes. In both cases, the researchers found that spontaneous regrowth of damaged axons through the scar did not occur. In addition, animals lacking the scar showed greater dieback of axons from the injury site than was seen in injured wild-type animals, suggesting that reactive astrocytes actually support injured neurons (Fig. 1b) .
In a second set of experiments, Anderson et al. genetically altered astrocytes to express a receptor for diphtheria toxin, before injuring the spinal cord and allowing a scar to form for five weeks. The researchers then ablated the scar by killing astrocytes with ultralow doses of diphtheria toxin. Again, axons failed to regrow through regions depleted of reactive astrocytes. More over, the authors observed pronounced tissue degeneration and found that a larger area contained no axons in the astrocyte-scar-free injuries than under control injury conditions. These data demonstrate that, rather than being detrimental to neuronal health and regenerative capacity, the chronic astrocyte scar is crucial for sustained tissue integrity -upending the long-held dogma.
If reactive astrocytes are inhibitory as previously reported 3 , might they exert this effect by altering the extracellular environment to inhibit axon regrowth, for example by up regulating molecules called chondroitin sulfate proteoglycans (CSPGs) that inhibit growth? Anderson et al. show that levels of such CSPGs are indeed significantly higher in the injured spinal cord than in the same region of control, uninjured animals. But, surprisingly, when the scar was removed, CSPG levels did not fall, and growth-promoting CSPGs were also upregulated in scar-forming astrocytes. Moreover, aggrecan -a classic growth-inhibitory CSPG used in cell-culture experiments as a measure of reactiveastrocyte inhibition of axon regrowth -was not detected in scar-forming astrocytes. Thus, the glial scar is not the primary source of inhibitory CSPGs, quashing another theory.
Axons do not grow by default, but rely on external stimulatory growth cues. Anderson et al. next injected a gel containing growthpromoting factors (the neurotrophins NT3 and BDNF) into the injury site to activate neuronal growth programs. This stimulated axons to robustly regrow directly through the dense astrocytic scar tissue (Fig. 1c) . In fact, the authors found axons growing along reactive astrocytes. When the scar was removed, neurotrophins alone did not foster axon regrowth. Taken together, these data provide powerful evidence that astrocyte-scar formation aids, rather than inhibits, axon regeneration after injury.
How can these findings be squared with previous studies suggesting that the glial scar is strongly inhibitory? For one thing, other inhibitory cell types, such as fibroblasts and pericytes 9 , also contribute to the glial scar. In addition, one study 10 has identified different types of reactive astrocyte. It is therefore possible that, in previous studies, different types of injury produced different types of reactive astrocyte, with some types being inhibitory and others not.
Going forward, it will be important to define the signalling mechanisms that induce activation of the different types of reactive astrocyte. Studies of each cell type should then define their functions, whether they can inhibit axon growth and the molecular mechanisms that underlie their roles. This knowledge could enable the selective manipulation of certain astrocytes by specific molecules, which is preferable to deleting an entire cell population that may well both promote and inhibit axon regrowth. In any case, Anderson 
